NIH Psilocybin Research Speaker Series (Registration)

Submitted by nusratyj on Tue, 04/13/2021 - 14:50


Please use the form below to select the seminar series you would like to attend.


OMB No.: 0925-0740
Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 3 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.



Select all upcoming seminars you would like to attend:

3:00-4:00 PM EST -  Psilocybin at the End of Life
Charles Grob, M.D. Professor of Psychiatry and Pediatrics, UCLA School of Medicine

4:00-5:00 PM EST -  Psilocybin: Neuropsychopharmacology and Implications for Therapeutics
Roland Griffiths, Ph.D. Professor of Psychiatry and Behavioral Sciences, JHU School of Medicine
11:00-12:00 PM EST  - What’s at Stake, Strategic Science Policy Considerations for Advancing Public Health through Dynamic Regulatory Frameworks
Sean Belouin, Pharm.D. CAPT, United States Public Health Service, Senior Science Policy Advisor, SAMHSA

12:00-12:45 PM EST - A Breast Cancer Patient’s Perspectives on the Uses of Psychedelics in Medicine
Erica Rex, MA. Journalist & Writer for Scientific American and The New York Times, National Magazine Award Winner.

12:45-1:30 PM EST - Psilocybin in Cancer Patients with Depression---The Experience at Aquilino Cancer Center
Manish Agrawal, M.D. Cancer center Director, Aquilino Cancer Center

12:30 -1:00 pm EST - Low Doses of Psilocybin Enhance Motivation and Attention in Poor Performing Rats
Edward Sellers MD, PhD. Professor Emeritus, Pharmacology and Toxicology, Medicine and Psychiatry, University of Toronto, Canada

1:00-1:30 pm EST  -  Self-blinding Citizen Science to Explore Psychedelic Microdosing
Balázs Szigeti, PhD. Center for Psychedelic Research, Imperial College London, England

1:30-2:30 pm EST Psilocybin and Group Therapy: Implications for Safety and Efficacy
Brian Anderson, M.D, MSC. Assistant Professor, Psychiatry, UCSF School of Medicine Alicia Danforth, Ph.D. Clinical Psychologist

2:30-3:00 pm EST - Abuse Potential Related Science and Regulatory Perspectives for Psychedelic Drug Product Development
Jack Henningfield, PhD. Vice President, Research, Health Policy, And Abuse Liability, PinneyAssociates, and Adjunct Professor, Behavioral Biology, Dept. Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine

3:00-3:30 pm EST - Special Considerations for Evaluating Psilocybin-facilitated Treatments in Vulnerable Populations
Peter Hendricks, PhD. Professor & Director of Research, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham

2:00-2:45 PM EST - New Insights into the Mechanism of Action of Psilocybin

2:45-3:20 PM EST - Antidepressant-like and anti-inflammatory effects of psychedelics in rodent preclinical models
Charles Nichols, PhD. Professor, Department of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center

3:20-4:00 PM EST - Harnessing psilocybin to fight depression: Insights and provocations from preclinical studies
Scott Thompson, Ph.D. Professor and Chair, Department of Physiology, UMD School of Medicine

4:00-4:30 PM EST - Synthesis, characterization, and preclinical pharmacology of psilocybin analogs and related tryptamines
Grant Glatfelter, Ph.D. Postdoctoral Fellow, Designer Drug Research Unit, IRP, NIDA, NIH

12:30- 1:00 PM EST - Psychedelics in Headache Medicine: Historical, Neuropharmacological, Neuroanatomical, and Clinical Evidence
Emmanuelle Schindler, MD, PhD. Assistant Professor of Neurology, Yale School of Medicine, Medical Director, Headache Center of Excellence, VA Connecticut Healthcare System

1:00-1:40 PM EST - Psilocybin-Assisted Psychotherapy for Advanced Cancer-related Psychiatric and Existential Distress
Stephen Ross, M.D. Associate Professor, Department of Psychiatry at NYU Grossman School of Medicine

1:40-2:15 pm - EST Psychedelic Medicine and Ethics
Paul S. Appelbaum, MD. Dollard Professor of Psychiatry, Medicine, & Law, Columbia University College of Physicians & Surgeons
Mason Marks, MD, JD. Assistant Professor of Law, Gonzaga University
William Smith, MD, PhD, Psychiatry Resident, Perelman School of Medicine, University of Pennsylvania

2:15-3:45 PM EST - Final Panel Discussion

  • All speakers
  • Event Planning Committee
  • Sharmin Ghaznavi, M.D, Ph.D., Associate Director, Center for the Neuroscience of Psychedelics, and Director of Center’s Cognitive Neuroscience, Massachusetts General Hospital
  • Michael Silver, Ph.D. Director, UC Berkeley Center for the Science of Psychedelics
  • Stephen Xenakis, M.D. Brigadier General (Ret), U.S. Army
  • Marta Sokolowska, Ph.D. Associate Director for Controlled Substances, Center for Drug Evaluation and Research (CDER), FDA
  • Frank Weichold, M.D., Ph.D. Senior Science Advisor for the office of the Chief Scientist and the Office of the Commissioner, FDA
  • Susan Weiss, Ph.D. Director, Division of Extramural Research, NIDA, NIH
  • Steve Zalcman, M.D. Chief, Adult Pathophysiology and Biological Interventions Branch, Division of Translational Research, NIMH, NIH

Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact Dr. Terry Moody,, 240-276-7785, or Dr. Dan Xi,, 240-276-6143, and/or the Federal Relay (1-800-877-8339) 2 days before the event.